Induction of CD3+ and FoxP3+ T Cells in Left-sided Colorectal Tumors After UFT/LV Chemotherapy.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 03 03 2019
revised: 17 03 2019
accepted: 18 03 2019
entrez: 7 4 2019
pubmed: 7 4 2019
medline: 16 4 2019
Statut: ppublish

Résumé

Immune checkpoint inhibitors are mainly used for right-sided, microsatellite instability-high colorectal tumors. In this study, the effects of oral uracil-tegafur plus leucovorin (UFT/LV) chemotherapy on the gene expressions of four immunotherapy targets and the amounts of tumor-infiltrating lymphocytes (TILs) were investigated. Data of 260 patients with stage II or stage III colorectal cancer were analyzed. Gene expression and amount of TILs were evaluated using real-time reverse transcription polymerase chain reaction (CRT-PCR) assay and immunohistochemical staining, respectively. Expression of CTLA4 and LAG3 in tumor tissues was significantly increased after UFT/LV chemotherapy, but only in left-sided tumors. The percentage of high-TIL, high-CD3 and high-FoxP3 patients in the UFT/LV group was significantly higher than that in the control group, only in left-sided tumors. The increase in TILs count, especially of CD3+ T cells and FoxP3+ regulatory T cells, after UFT/LV chemotherapy were specific to left-sided colorectal cancers.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Immune checkpoint inhibitors are mainly used for right-sided, microsatellite instability-high colorectal tumors. In this study, the effects of oral uracil-tegafur plus leucovorin (UFT/LV) chemotherapy on the gene expressions of four immunotherapy targets and the amounts of tumor-infiltrating lymphocytes (TILs) were investigated.
PATIENTS AND METHODS METHODS
Data of 260 patients with stage II or stage III colorectal cancer were analyzed. Gene expression and amount of TILs were evaluated using real-time reverse transcription polymerase chain reaction (CRT-PCR) assay and immunohistochemical staining, respectively.
RESULTS RESULTS
Expression of CTLA4 and LAG3 in tumor tissues was significantly increased after UFT/LV chemotherapy, but only in left-sided tumors. The percentage of high-TIL, high-CD3 and high-FoxP3 patients in the UFT/LV group was significantly higher than that in the control group, only in left-sided tumors.
CONCLUSION CONCLUSIONS
The increase in TILs count, especially of CD3+ T cells and FoxP3+ regulatory T cells, after UFT/LV chemotherapy were specific to left-sided colorectal cancers.

Identifiants

pubmed: 30952743
pii: 39/4/1997
doi: 10.21873/anticanres.13310
doi:

Substances chimiques

Antigens, CD 0
CD3 Complex 0
CTLA-4 Antigen 0
CTLA4 protein, human 0
FOXP3 protein, human 0
Forkhead Transcription Factors 0
Tegafur 1548R74NSZ
Uracil 56HH86ZVCT
Leucovorin Q573I9DVLP
Lymphocyte Activation Gene 3 Protein 0
Lag3 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1997-2005

Informations de copyright

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Sotaro Sadahiro (S)

Department of Surgery, Tokai University School of Medicine, Isehara, Japan Sadahiro@is.icc.u-tokai.ac.jp.

Toshiyuki Suzuki (T)

Department of Surgery, Tokai University School of Medicine, Isehara, Japan.

Akira Tanaka (A)

Department of Surgery, Tokai University School of Medicine, Isehara, Japan.

Kazutake Okada (K)

Department of Surgery, Tokai University School of Medicine, Isehara, Japan.

Gota Saito (G)

Department of Surgery, Tokai University School of Medicine, Isehara, Japan.

Hiroshi Miyakita (H)

Department of Surgery, Tokai University School of Medicine, Isehara, Japan.

Lin Fung Chan (LF)

Department of Surgery, Tokai University School of Medicine, Isehara, Japan.

Yutaro Kamei (Y)

Department of Surgery, Tokai University School of Medicine, Isehara, Japan.

Hiroshi Kajiwara (H)

Department of Pathology, Tokai University School of Medicine, Isehara, Japan.

Hideki Nagase (H)

Pharmacology Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH